

[Melarsoprol](#)

Essential medicine status

Section:

[6. Anti-infective medicines](#) [6.5. Antiprotozoal medicines](#) [6.5.5. Antitrypanosomal medicines](#) [6.5.5.1. African trypanosomiasis](#) [6.5.5.1.2. Medicines for the treatment of 2nd stage African trypanosomiasis](#)

ATC codes: [P01CD01](#)

EMLc

Indication

Gambiense trypanosomiasis ICD11 code: [1F51.0](#)

INN

Melarsoprol

Medicine type

Chemical agent

List type

Core (EML)

Complementary (EMLc)

Formulations

Parenteral > General injections > IV: 3.6% in 5 mL ampoule solution (180 mg of active compound)

EML status history

First added in 1977 ([TRS 615](#))

Changed in 1979 ([TRS 641](#))

Changed in 1987 ([TRS 770](#))

Changed in 2007 ([TRS 946](#))

Changed in 2007 ([TRS 950](#))

Changed in 2009 ([TRS 958](#))

Sex

All

Age

Also recommended for children

Therapeutic alternatives

The recommendation is for this specific medicine

Patent information

Patents have expired in most jurisdictions

Read more [about patents](#).

Wikipedia

[Melarsoprol](#)

DrugBank

[Melarsoprol](#)

Summary of evidence and Expert Committee recommendations

Melarsoprol was moved to the Complementary List of the EMLc due to safety concerns of its use in children.